Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Apomorphine-induced changes in synaptic dopamine levels: Positron emissiontomography evidence for presynaptic inhibition
Autore:
de la Fuente-Fernandez, R; Lim, AS; Sossi, V; Holden, JE; Calne, DB; Ruth, TJ; Stoessl, AJ;
Indirizzi:
Univ British Columbia, Ctr Neurodegenerat Disorders, Vancouver, BC V5Z 1M9, Canada Univ British Columbia Vancouver BC Canada V5Z 1M9 ver, BC V5Z 1M9, Canada Univ Wisconsin, Madison, WI USA Univ Wisconsin Madison WI USAUniv Wisconsin, Madison, WI USA
Titolo Testata:
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
fascicolo: 10, volume: 21, anno: 2001,
pagine: 1151 - 1159
SICI:
0271-678X(200110)21:10<1151:ACISDL>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMINO-ACID DECARBOXYLASE; EARLY PARKINSONS-DISEASE; C-11 RACLOPRIDE BINDING; HUMAN-BRAIN; D2-DOPAMINE RECEPTOR; AFFINITY STATES; H-3 RACLOPRIDE; BLOOD-FLOW; PET; STRIATUM;
Keywords:
dopamine release; motor complications; Parkinson disease; presynaptic inhibition; PET; raclopride;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Stoessl, AJ Vancouver Hosp & Hlth Sci Ctr, Ctr Neurodegenerat Disorders, Purdy Pavil,2221 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada Vancouver Hosp& Hlth Sci Ctr Purdy Pavil,2221 Wesbrook Mall Vancouver BC Canada V6T 2B5
Citazione:
R. de la Fuente-Fernandez et al., "Apomorphine-induced changes in synaptic dopamine levels: Positron emissiontomography evidence for presynaptic inhibition", J CEREBR B, 21(10), 2001, pp. 1151-1159

Abstract

The authors developed a novel positron emission tomography method to estimate changes in the synaptic level of dopamine ([DA]) induced by direct dopamine agonists (for example, apomorphine) in patients with Parkinson disease. The method is based on the typical asymmetry of the nigrostriatal lesion that often occurs in Parkinson disease. Using the between-side difference (ipsilateral (I) and contralateral (C) putamen to the more affected body side) of the inverse of the putamen [C-11]raclopride binding potential (BP), the authors obtained1/BPI - 1/BPC = K-D/BmaxKDA([DA](I) - [DA](C))at baseline (that is, before apomorphine administration) and1/BPI' - 1/BPC' = K-D/BmaxKDA([DA](I)' - [DA](C)')after apomorphine administration (assuming the concentration of apomorphine is equal in both putamina). The between-side difference in the estimated synaptic concentration of dopamine (diff[DA]) should remain constant unlessapomorphine affects dopamine release differently between the two sides. The authors found that apomorphine given subcutaneously at doses of 0.03 and 0.06 mg/kg induced significant changes in their estimate of diff[DA] (P < 0.05). Such changes were more pronounced when only patients with a stable response to levodopa were considered (P < 0.01). These findings provide in vivo evidence that direct dopamine agonists can inhibit the release of endogenous dopamine. The authors propose that this effect is mainly mediated by the activation of presynaptic D-2/D-3 dopamine receptors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 07:30:38